Onco-hematological Tumors Unit
What does the Unit treat?
The Onco-hematological Tumors Unit is a national reference, specialized in the treatment of leukemias, lymphomas, and multiple myeloma.
At HM Hospitals (CIOCC), the Onco-hematological Tumors Unit focuses on:
- Development of clinical trials aimed at patients with lymphomas and multiple myeloma based on bispecific antibodies and CAR-T therapy.
Related Diseases
- Hodgkin’s Lymphoma.
- Multiple Myeloma.
- Lymphocytic Leukemia.
- Leukemia.
- Lymphoma.
Who is this Unit for?
The Onco-hematological Tumors Unit is aimed at:
- Patients with leukemias, lymphomas, and multiple myeloma.
- Patients seeking to participate in clinical trials with bispecific antibodies and CAR-T therapy.
- Family members and caregivers seeking information and support for their loved ones with onco-hematological tumors.
- Healthcare professionals who wish to refer patients for specialized onco-hematological tumor evaluation and treatment.
How do we approach it at HM Hospitals?
Cell Therapy (CAR-T, TILs)
We modify the patient’s own immune cells to recognize and destroy cancer cells more effectively.
Advanced Immunotherapy
We stimulate the immune system to attack cancer cells, leveraging its natural ability to fight the disease.
Latest generation oncological drugs
Selective attack on tumor cells. We use innovative drugs that attack cancer cells more selectively, minimizing side effects.
Oncological Robotic Surgery
We perform complex surgeries with greater precision, less bleeding, and faster recovery thanks to robotic assistance.
Adaptive Radiotherapy
We adjust radiotherapy to the changes that occur in the tumor during treatment, maximizing its effectiveness and protecting healthy tissues.
Targeted Radioisotopes (nuclear medicine)
We selectively direct radiation to tumor cells, minimizing damage to surrounding healthy tissues.
Metabolic therapy
We alter the metabolism of tumor cells to inhibit their growth and spread.